Company: CERO
Filing Date: 2025-04-25
Form Type: PRE 14A
Source: 0001213900-25-035562
Chunk: 8

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-25
Form: PRE 14A
Chunk 8
---
 conditions, of the issuance of shares of Common Stock in accordance with Nasdaq Listing Rule 5635, upon the exercise of warrants to purchase Common Stock (the “February 2025 Common Warrants”) issued in a registered direct offering in February 2025 (the “February 2025 Registered Direct Offering”) at less than the “minimum price” under Nasdaq Listing Rule 5635(d), including the issuance of equity compensation to one of the Company’s directors upon the exercise of the February 2025 Common Warrants at less than market value pursuant to Nasdaq Listing Rule 5635(c) (the “Nasdaq Share Issuance (Warrants) Proposal” or “Proposal No. 2”). • Proposal No. 3:The approval, subject to certain conditions, of the issuance of shares of Common Stock in accordance with Nasdaq Listing Rule 5635 upon the conversion of the Company’s Series D convertible preferred stock, par value $0.0001 per share (the “Series D Preferred Stock”), issued in a private placement in April 2025 (the “April 2025 Private Placement”), at less than the “minimum price” under Nasdaq Listing Rule 5635(d) (the “Nasdaq Share Issuance (Series D) Proposal” or “Proposal No. 3”) • Proposal No. 4 :The approval of the CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan (the “2024 Plan”), as amended to increase the number of shares of Common Stock available for issuance under the 2024 Plan and the number of shares that may be issued pursuant to incentive stock options by an additional shares (the “Plan Share Increase Proposal” or “Proposal No. 4”). • Proposal No. 5 :The approval of the election of two Class I directors to the Board, to serve until the 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal (the “Director Election Proposal” or “Proposal No. 5”); 1 • Proposal No. 6 :The ratification of the appointment of Wolf & Company, P.C. (“Wolf”), as the Company’s independent registered public accounting firm for the 2025 fiscal year (the “Auditor Ratification Proposal” or “Proposal No. 6”); and • Proposal No. 7 :The approval of an adjournment of the Annual Meeting,